Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Dr. Hoenle AG ( (DE:HNL) ) is now available.
Hoenle AG has strengthened its top management by confirming Dr. Franz Richter as a member and chairman of the Management Board for a three-year term, extending his contract as CEO until February 28, 2029. Having already taken over the CEO role on October 1, 2025, with his Supervisory Board mandate suspended since then, Richter will formally resign from the Supervisory Board at the end of February 2026 and focus on steering the Hoenle Group back to a trajectory of profitable growth, signaling a strategic push to reinforce leadership stability and improve the company’s operational and financial performance.
The most recent analyst rating on (DE:HNL) stock is a Sell with a EUR7.00 price target. To see the full list of analyst forecasts on Dr. Hoenle AG stock, see the DE:HNL Stock Forecast page.
More about Dr. Hoenle AG
Hoenle AG is a publicly listed German technology company headquartered in Gilching that specializes in UV technology solutions for a wide range of industrial applications. With around 600 employees, the group develops and markets industrial adhesives and adhesive-curing equipment, systems for ink and coating curing for the printing and coatings industries, and environmentally friendly disinfection systems for water, air, and surfaces, serving leading global technology and market leaders in more than 20 countries through its own subsidiaries and partner companies.
YTD Price Performance: 34.01%
Average Trading Volume: 8,363
Technical Sentiment Signal: Sell
Current Market Cap: €56.38M
Find detailed analytics on HNL stock on TipRanks’ Stock Analysis page.